HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Telegram Restored on Apple App Store After Temporary Removal 
VANCOUVER, British Columbia, April 09, 2018 -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) (OTCQB:RVVQF) (Frankfurt:1IT) today announced that it has secured DTC Eligibility for its common shares listed on the OTC market in the United States.
About the Depository Trust Company
The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corporation DTCC and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
“George Robinson”
Chief Executive Officer
For further information, please contact:
Mathieu McDonald, Corporate Communications – 604-484-1230
Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
